Neovascular age-related macular degeneration (nAMD) research hub
7 indexed studies · 3 currently recruiting
- authorisedPhase II and Phase III (Integrated)
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
This study tests a new eye injection called OCUL101 for wet age-related macular degeneration (wet AMD). Researchers want to see how safe it is and if it works as well as or better than Eylea, a standard NHS eye treatment, at protecting or improving sight.
Latvia · Poland · Czechia - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
This study is looking into a new treatment, RBS-001, for a specific eye condition called wet age-related macular degeneration (wet AMD). It compares RBS-001 with an existing treatment, Eylea, to see if it works as well or better, and if it's safe for patients.
Bulgaria · Croatia · Slovakia - recruitingPhase III
A study to investigate if Levodopa (a Parkinson’s medication) can help people with wet age-related macular degeneration
This UK study tests whether a tablet commonly used for Parkinson’s disease can help people with wet age-related macular degeneration (wet AMD). Researchers want to find out if taking this tablet alongside standard care can protect sight while reducing the number of eye injections patients need.
United Kingdom · England - recruitingPHASE3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This study is for people with wet macular degeneration, a common eye condition. It's testing a new, single injection treatment (4D-150) against a standard treatment (Eylea) to see if it can help improve or maintain vision. The goal is to find a longer-lasting solution.
United States · Argentina · Australia - active not recruitingPHASE4
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This study is looking at a new treatment called faricimab for a common eye condition called 'wet' Age-related Macular Degeneration (AMD). It aims to see how well it works, if it's safe, and how long its effects last when given less often.
United States · Australia · Canada - active not recruitingPHASE3
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
This study looks at a new way to treat a common eye condition called 'wet' Age-related Macular Degeneration (nAMD). It tests how well a special eye implant works, which slowly releases medicine over a long time, compared to standard eye injections.
Argentina · Australia · Austria - active not recruiting
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
The SPECTRUM Study is looking at how well a new eye medicine called aflibercept 8 mg works for vision problems caused by wet AMD or diabetic macular oedema. Researchers will collect information from patients who are already prescribed this medicine by their doctor.
Australia · Canada · Denmark